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Objectives: Health care resource utilization and costs were evaluated for patients 
diagnosed with multiple sclerosis (MS) in the U. S. Medicaid program. MethOds: 
Patients diagnosed with MS (International Classification of Disease, 9thRevision, 
Clinical Modification [ICD-9-CM] diagnosis code 340) were identified using Medicaid 
data from 01JAN2008 through 31DEC2010. The initial diagnosis date was designated 
as the index date. Patients of the same age, race, and gender but without an MS 
diagnosis were identified and matched as the comparison cohort, with a randomly 
chosen index date to minimize selection bias. Patients in both groups were required 
to be at least age 18 years, and have continuous medical and pharmacy benefits 
1 year before and 1 year post-index date. One-to-one propensity score matching 
(PSM) was used to compare health care costs and utilizations during the follow-up 
period, between the diseased and the comparison cohorts, and adjusted for baseline 
demographic and clinical characteristics. Results: After risk adjustment by PSM, a 
total of 14,179 patients in each cohort were matched. Significantly more MS patients 
had inpatient admissions (23.75% vs. 10.87%, p< 0.0001) and long-term care (22.64% 
vs. 4.13%, p< 0.0001), other service (99.70% vs. 89.00%, p< 0.0001) and pharmacy visits 
(73.08% vs. 67.71%, p< 0.0001) compared to those without an MS diagnosis. Higher 
health care utilization by MS patients led to significantly higher inpatient ($1,688 
vs. $725, p< 0.0001), long-term care ($14,189 vs. $2,778, p< 0.0001), other service visit 
($22,981 vs. $9,977, p< 0.0001) and pharmacy costs ($5,284 vs. $1,785, p< 0.0001) com-
pared to those without MS. cOnclusiOns: Compared to patients in the comparator 
cohort, MS patients in the Medicaid program incurred substantially higher health 
care resource utilization and costs.
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Objectives: CUA of teriflunomide and first-line DMTs (glatiramer acetate (GA), 
interferon-β -1a (IFNβ -1a: intramuscular IM, or subcutaneous SC) or interferon-β -1b 
(IFNβ -1b)), compared to BSC in Finnish RRMS-patients. MethOds: Register study 
and Markov cohort modelling. During the 50-year time horizon, patients could stay 
or progress to another Expanded Disability Status Scale (EDSS) state, experience 
relapse (with/without hospitalisation), adverse events (AEs) or death. EQ-5D utili-
ties were derived from literature, and Finnish costs (health care 2013; official drug 
costs 4/2014 without VAT) were associated with EDSS, relapses, and AEs. Indirect 
treatment comparison informed treatment effects. EDSS-related standardised mor-
tality ratios (SMR) and RRMS-progression were analysed from Finnish MS-register 
(Tampere, Vaasa, Seinäjoki regions; 1359 patients). Other health risks were based 
on literature. Cohort characteristics were estimated from a subgroup (713 patients, 
clinically confirmed RRMS, age, gender and EDSS 0–6.5 at first DMT initiation). 
Caregiver’s disutility, Finnish productivity losses, and informal care costs were 
included in sensitivity analysis (societal perspective). Costs and quality-adjusted 
life-years (QALYs) were discounted with 3%/year. Results: Expected lifetime health 
care [societal] costs per patient were: teriflunomide: € 798,864 [€ 1,596,570], IFNβ -1a-
SC: € 805,069 [€ 1,618,344], IFNβ -1b: € 826,633 [€ 1,647,745], GA: € 823,438 [€ 1,649,961], 
IFNβ -1a-IM: € 820,516 [€ 1,645,472], and BSC: € 788,932 [€ 1,626,554]. Respective QALYs 
were 6.55 [5.44], 6.27 [5.13], 6.15 [4.99], 6.05 [4.88], 6.04 [4.87], and 5.79 [4.60]. From 
the payer [societal] perspective, incremental cost per QALY gained of teriflunomide 
was € 13,089 [dominant] relative to BSC, and teriflunomide dominated other first-
line DMTs. Teriflunomide had 83% [per-patient expected value of perfect informa-
tion, EVPI € 241], 98% [EVPI € 22], and 100% [EVPI € 0] cost-effectiveness probability 
with € 0, € 10,000, and € 20,000 per additional QALY, respectively. cOnclusiOns: 
Cost-effectiveness analyses of first-line DMTs compared to BSC showed that teri-
flunomide provided lowest cost and highest number of QALYs and was therefore 
dominant over IFNβ s and GA for Finnish RRMS patients.
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Objectives: To estimate the cost-effectiveness of intrathecal baclofen ther-
apy (ITB) against conventional medical management (CMM) in non-focal 
disabling spasticity (N-FDS) patients who are resistant or intolerant to oral ther-
apy. MethOds: A markov model was developed to estimate clinical and economic 
outcomes for patients treated with ITB or CMM. Treatment effects, patients´ base-
line characteristics, resource utilization and health utility values were taken from 
the EPICE study. The model was built in accordance with the Institut Guttmann´s 
clinical practice, a reference center in Spain. Unit costs were obtained from the 
cited center. The analysis was conducted from the Institut Guttmann´s perspec-
tive over a lifetime horizon with direct medical costs (2013) and outcomes dis-
counted at 3%. Uncertainty was assessed through univariate and multivariate 
sensitivity analysis (SA). Results: When comparing ITB with CMM, the model 
estimates ITB would increase remaining lifetime costs by € 35,605 and result in a 
QALY gain of 1.06; thus showing an incremental cost-effectiveness ratio (ICER) of 
€ 33,619 per QALY gained. SA reflecting the most current clinical practice at the 
Institut Guttmann (where now a new catheter, associated with an 80% reduction 
in adverse events, is used) showed an ICER of € 27,805 per QALY gained. ICER 
results were also sensitive to changes in the post-operation hospitalization period, 
baclofen dose titration management, pump battery life, and health utility val-
ues. cOnclusiOns: The present evaluation results in an ICER of ITB against CMM, 
in the treatment of N-FDS patients who are resistant or intolerant to oral therapy 
at the Institut Guttmann, close to a willingness-to-pay threshold of € 30,000 per 
states: Expanded Disability Status Scale (EDSS) 0-9 for patients with RRMS and 
secondary progressive multiple sclerosis (SPMS), respectively, and death (EDSS10). 
Total treatment costs, quality-adjusted life-years (QALYs) gained and incremental 
cost-effectiveness ratios (ICERs) were calculated from the Dutch societal perspec-
tive. Baseline demographics; transition probabilities; treatment-specific relative 
risks; and utility values were obtained from published literature. Health resource 
use was based on the products’ SmPCs. Unit costs were based on national tar-
iffs and published data. A base case analysis considered the direct and indirect 
costs of treatment. To test the robustness of the results, univariate and probabil-
istic sensitivity analyses (PSA) were performed. Results: Total treatment costs 
of glatiramer acetate were lower versus teriflunomide, interferon-beta-1a 44mcg, 
30mcg, fingolimod, natalizumab, dimethyl fumarate and alemtuzumab; and higher 
versus interferon-beta-1a 22mcg, interferon-beta-1b, and BSC. Glatiramer acetate 
dominated interferon-beta-1a 44mcg and 30mcg, and was cost-effective versus 
other comparators at a willingness-to-pay threshold of € 20,000/QALY. The PSA 
indicated these results were robust. Univariate analysis showed that relative risks 
of disease progression and drug costs were the most influential model param-
eters. cOnclusiOns: In the Netherlands, glatiramer acetate is a cost-effective 
treatment versus a number of other treatments indicated in multiple sclerosis, 
and results proved robust.
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Objectives: To calculate the expected value of partial perfect information (EVPPI) 
of the disability progression efficacy for teriflunomide and fingolimod in relapsing-
remitting multiple sclerosis (RRMS) and investigate the potential differences between 
these two disease modifying therapies (DMTs). MethOds: A cohort Markov model 
based on the ScHARR model structure was developed from the UK NHS perspective, 
which allows the cost-effectiveness of the DMTs to be calculated and also has the 
additional ability to calculate the EVPPIs for progression efficacies. The evaluated 
intervention consists of beta-interferons followed by fingolimod. The comparator 
treatment includes beta-interferon therapy followed by teriflunomide. The EVPPIs 
for both drugs were calculated and compared. Results: The EVPPIs varied substan-
tially depending on the evaluated drug and the specific willingness-to-pay (WTP). 
Although both EVPPI curves had a similar shape, the curve for teriflunomide had an 
EVPPI equal or larger compared to fingolimod’s curve for every WTP value. At a WTP 
of £30,000 per QALY, the EVPPI per patient of teriflunomide and fingolimod were 
£252 and £50, respectively. In the sensitivity analysis, where the uncertainty around 
the estimate of teriflunomide progression efficacy was artificially lowered to that of 
fingolimod, the divergence between the EVPPI curves was reduced substantially, con-
firming that the uncertainty around teriflunomide progression efficacy is driving its 
higher EVPPI. cOnclusiOns: Higher EVPPI estimates of teriflunomide indicate that 
the precise knowledge of the disability progression efficacy of teriflunomide would 
be considerably more valuable to the decision maker than that of fingolimod. One 
of the main factors affecting larger EVPPI of teriflunomide’s progression efficacy is a 
higher uncertainty concerning effects of teriflunomide. There are, however, many data 
limitations and uncertainties within the DMT modelling. Additionally, the expected 
value of sample information analysis (EVSI) would be required in order to evaluate 
more precisely the cost-effectiveness of additional clinical trials.
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Objectives: Colistimethate sodium (Colistin) is an old, “forgotten” antibiotics 
revived due to multidrug-resistant Gram-negative bacteria in nosocomial infec-
tions. In many countries, both – intravenous and inhalational administrations of 
Colistin have marketing authorisation. In Serbia, Colistin is registered only for 
intravenous administration. Therefore, inhalational administration of Colistin in 
treatment for cystic fibrosis is considered as off label use. AiM: The purpose of 
this study was to assess benefits of Colistin off label use, currently available in 
Serbia, for treatment for cystic fibrosis. MethOds: Data collected from a review 
of the literature (Pubmed searching key word off label, Colistin, Tobramycine, cost 
minimisation) and data from Health Insurance Fond of Republic Serbia (2014) 
were used to perform a cost-minimisation analysis comparing DDD in inhalation 
administration of Colistin with Tobramycin (official methodology in Serbia for drug 
reimbursement Listing). Results: Both, Colistin and Tobramycine are effective 
in cystic fibrosis treatment. The cost of treatment per patient per year in Serbia is 
3 616,00 Euro for Colistin and 5 950,00 Euro for Tobramycin. Total savings per year 
for 200 registered patients in Serbia could be 466 857,00 Euro. cOnclusiOns: 
Given cost-minimisation analysis justified the treatment with Colistin as cost 
saving therapeutic alternative to Tobramycin for cystic fibrosis patients in Serbia. 
The lack of guidelines and principles regarding off label medicine use in health 
care policy and decision making in Serbia was evidently an obstacle for better 
patients care.
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survey contained demographic, disease characteristic and health care experience 
variables, which were evaluated as potential predictors of DMD adherence using 
logistic regression, controlling for age and gender. No adjustment was made for 
multiplicity. Results: 969 patients completed the survey; 579 met analysis crite-
ria. High vs. intermediate/low adherers represented 47.7% and 52.3%, respectively. 
Average age for high adherers was 49.1 (SD: 10.9), 81.5% female; intermediate/
low adherers had an average age of 47.3 (SD: 11.4), 87.7% female. Of 149 variables, 
the following were associated with greater odds of high adherence: detailed dis-
cussions with health care professional about “how long the treatment had been 
available” (p= 0.02; OR: 1.47; high 56.8% vs. intermediate/low 47.1%) or “long-term 
safety” (p= 0.01; OR: 1.54; high 54.8% vs. intermediate/low 44.2%); satisfaction with 
DMD (p= 0.04; OR: 1.14; high 5.4 [SD: 1.4] vs. intermediate/low 5.2 [SD: 1.3] ); or 
insurance covered entire cost of DMD (p= 0.01; OR: 1.71; high 23.1% vs. intermedi-
ate/low 15.2%). Results indicating lower odds of high adherence included longer 
duration on current therapy (p< 0.01; OR: 0.99; high 63.2 [SD: 53.5] months vs. inter-
mediate/low 75.9 [SD: 60.0] months) and cost made them “skip a dose” (p< 0.01; 
OR: 0.37; high 5.3% vs. intermediate/low 13.4%) or “not fill or refill a prescription” 
(p< 0.01; OR: 0.43; high 5.3% vs. intermediate/low 12.0%). cOnclusiOns: Patient 
and provider dialogue, patient satisfaction with treatment and health plan benefit 
design aspects may affect DMD adherence.
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(DMt) AND its iNDePeNDeNt DriVers iN fiNNish MUltiPle sClerosis (Ms) 
PAtieNts: PArAMetriC sUrViVAl MoDelliNg
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Objectives: Explore how MS DMT-persistence can be modelled, compare model’s 
performance and assess the independent drivers for DMT-persistence. MethOds: 
Analysis was based on 1638 DMT uses (1.1. 1991–31.12.2010, time at risk 4009 years) 
in incident MS-patient register from Tampere, Vaasa and Seinäjoki regions, Finland. 
DMT-persistence = DMT end-day - DMT initiation day. Cox, exponential, general-
ized gamma, Gompertz, log-logistic, log-normal, and Weibull regression survival 
models were used to model DMT-persistence. Models were compared based on 
goodness-of-fit statistics (Akaike and Bayesian information criteria). Results: 
Mean follow-up from first MS-symptoms and age at first DMT-initiation were 13 
and 36 years, respectively. 73% of patients were female. Based on the data explo-
ration of all known covariates, three DMT-persistence approaches with different 
interpretations, selected covariates and data needs were modelled: 1] sex, birth 
year, time from symptoms to DMT, age, DMT line (1st, 2nd, 3rd, 4th, 5-7th), DMT 
(interferon-β -1a and -1b, glatiramer acetate, other) at DMT initiation; 2] approach 
1] + Expanded Disability Status Scale (EDSS) at DMT initiation; and 3] approach 2] 
+ DMT-discontinuation reason (pregnancy plan, flu-like symptoms, injection-site 
reactions, ineffectiveness, antibodies, other/unknown). There was no gold stand-
ard survival model for DMT-persistence, and some models accommodated higher 
number of covariates and associated dependencies better. For approaches 1] and 
2] Weibull and for 3] Gompertz model provided the best goodness-of-fit. Based on 
all three models (one per approach 1] –3]) with best goodness-of-fit, higher EDSS 
or higher age at DMT initiation, treatment line (3rd and later), and incidence of 
intolerable adverse events (AE) or ineffectiveness were independently associated 
with shorter DMT persistence. In the approach 3], flu-like symptom and injection 
site AEs had the highest hazard ratio for shorter DMT-persistence. cOnclusiOns: 
AEs, EDSS, age, treatment line and ineffectiveness were strong predictors for DMT-
persistence. Flu-like symptoms and injection site AEs showed the highest hazard 
for DMT-discontinuation.
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Objectives: To compare 6-month persistence rates among patients initiating the 
oral multiple sclerosis (MS) disease-modifying therapies (DMTs) fingolimod and 
dimethyl fumarate (DMF). MethOds: Our retrospective analysis used mail-order 
pharmacy claims from the US open-source LRx™ database (IMS). Patients with ≥ 1 
fingolimod or DMF prescription (index DMT) between 01-April-2013 and 31-July-
2013 were included. Patients were ≥ 18 years old, naive to fingolimod and DMF, and 
had not received multiple DMTs on the date of the first index DMT claim (index 
date). Prescription records were collected from pharmacies supplying ≥ 1 index 
DMT claim between the index date and the last month of follow-up. Persistence 
was assessed as time from initiating index DMT until discontinuation (gap of ≥ 60 
days), receipt of another DMT or the end of the 6-month follow-up period. The 
risk of and time to index DMT discontinuation was assessed using a Cox propor-
tional hazards model (controlling for age, gender and region) and Kaplan-Meier 
analysis, respectively. Results: The study included 9546 patients (fingolimod: 
n= 1390; DMF: n= 8156). The proportion of patients discontinuing index DMT was 
significantly lower for patients receiving fingolimod (23.3%) versus DMF (36.6%; 
p< 0.0001). The risk of discontinuation was 1.6-fold higher in the DMF cohort ver-
sus the fingolimod cohort (hazard ratio, 95% confidence intervals: 1.58, 1.41-1.77; 
p< 0.0001). Time to discontinuation was significantly longer with fingolimod than 
with DMF (p< 0.0001), resulting in a longer duration of therapy persistence for 
fingolimod versus DMF (mean ± standard deviation: 152±53 days versus 135±62 
days, respectively). Results were similar when discontinuation was defined as a 
gap of ≥ 30 days (p< 0.0001 for all outcomes). cOnclusiOns: This analysis provides 
the first insight into short-term persistence rates with oral DMTs. In a real-world 
setting, the risk of discontinuation over 6 months was lower for patients initiating 
fingolimod versus DMF.
QALY gained. However, SA results indicate that the ICER drops below this threshold 
when most current clinical practice at the cited center is considered. Moreover, SA 
results suggest potential ways to optimize the current clinical pathway in order 
to reduce procedure costs even further.
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bAckgROund: Familial chylomicronemia syndrome (FCS) is a rare genetic dis-
order characterized by deficiency of lipoprotein lipase, causing accumulation of 
chylomicrons. An estimated 0.1-0.2 per 100,000 people has FCS worldwide. FCS 
patients present massively elevated triglyceride levels (typically > 2,000 mg/dL), 
resulting in increased risk of recurring acute pancreatitis. Standard triglyceride 
lowering medications are ineffective for FCS patients, who rely on restrictive 
low fat diet to control their triglyceride. There is limited literature about long-
term progression, the burden of illness or consequences of acute pancreatitis for 
FCS. Objectives: To estimate long term disease progression, costs and conse-
quences of FCS. MethOds: An individual Monte Carlo simulation model was built 
to track disease progression of a cohort of FCS patients with a mean age of 37.8 
years, 60% male, and a mean triglyceride level of 2,741 mg/dL. The model projected 
the number of acute pancreatitis events, mortality and medical costs. Benefits 
of a hypothetical triglyceride reduction intervention were assessed. Results: 
With standard diet control, the average life expectancy of the studied cohort was 
estimated to be 16.45 years. These patients were expected to experience 10.16 
episodes of acute pancreatitis during their lifetime, resulting in 80.7 inpatient days. 
The discounted lifetime cost of acute pancreatitis was projected to be $154,126 
per patient. The cumulative mortality due to acute pancreatitis was estimated to 
be 54.3%. Should an intervention reduce triglyceride levels by 50% in FCS patients, 
the life expectancy would be increased by 3.16 years and 7.72 fewer episodes of 
acute pancreatitis would occur, preventing 61.21 inpatient days and saving 
$118,594 in medical cost. cOnclusiOns: FCS patients are at high risk of life-
threatening and costly acute pancreatitis. Reduction in triglyceride levels has a 
significant impact of morbidity and mortality associated with acute pancreatitis. 
An effective triglyceride lowering intervention could mitigate the consequences 
of FCS significantly.
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Objectives: Relapsing remitting multiple sclerosis (RRMS) is a chronic inflam-
matory disease that represents the most common chronic neurological disorder 
in young adults. RRMS often leads to disability and is a major cause of reduced 
working capacity due to neurological diseases. Aim of this study is to investigate 
patients’ working productivity during treatment with natalizumab. MethOds: 
RRMS-Patients treated with natalizumab for a maximum of three months prior to 
baseline were eligible for study participation. Patients completed the EQ-5D and 
a questionnaire focused on occupational status, working ability, and days absent 
from work at study start study, after 6 months and 12 months. Socio-demographic 
and clinical data were collected. Primary endpoint was work productivity, which 
is defined as hours worked. To estimate costs and cost offsets due to the therapy 
with natalizumab, an average monetary value per working hour has been calcu-
lated to value productivity monetarily. Results: Preliminary results including 95 
patients after 6 months of therapy show a significant increase in work productivity 
of 84 hours (p= 0.014) for the whole study population compared to baseline. The 
average reduction of days absent from work was 4.8 days compared to baseline. 
The increase in working hours leads to an average change of monetarily valued 
productivity per patient and half-year from 6,550.40€ at baseline to 7,600.35€ after 
6 months for the entire study population. A subgroup analysis has been run on 
the group of employed patients. The working hours increased significantly by 
63h per half-year (p= 0.025). cOnclusiOns: In this study, the preliminary results 
show a significant increase in work productivity, which leads to a significant 
increase in the monetary value of productivity, for RRMS-patients treated with 
natalizumab. An increase in working hours as well as a decrease in days absent 
from work led to an increase in monetarily valued productivity. Study was funded 
by Biogen-Idec.
NeUrologiCAl DisorDers – Patient-reported outcomes & Patient Preference 
studies
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Objectives: Identify predictors of multiple sclerosis (MS) disease-modifying drug 
(DMD) adherence. MethOds: A random sample of adult MS patients from the US 
National Health and Wellness Survey or Lightspeed Research panel completed an 
internet survey in Nov/Dec2012. Clinical trial–naïve subjects with relapsing-remit-
ting MS who were on their current DMD for ≥ 4months were included. Adherence 
was measured using the 4-item Morisky Scale. Patients were assigned to ‘high’ 
(negative response to all 4 questions: forget to take, careless at times about tak-
ing, stop if better, stop if worse) or ‘intermediate/low’ (any positive response). The 
